Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 177Lung Neoplasms 59Neoplasms 24Neoplasm Metastasis 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Mesothelioma, Malignant 12Carcinoma 11Colorectal Neoplasms 10Mesothelioma 9Meningeal Carcinomatosis 8Melanoma 7Brain Neoplasms 7Pancreatic Neoplasms 6Adenocarcinoma of Lung 6Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Non-squamous Non-small Cell Lung Cancer 3Neoplasms by Histologic Type 3NSCLC 3Lung Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Bronchogenic 3Adenocarcinoma 3Thoracic Neoplasms 2

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Pemetrexed × 1 year × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡